Switzerland runs one of the world’s most defensive equity markets and one of its most concentrated. The Swiss Market Index holds twenty blue chips, and three of them — Nestlé, Roche and Novartis — have historically represented around half its weight. An SMI ETF is therefore not really a country fund. It is a concentrated position in global food and pharmaceuticals, with a Swiss franc attached.
That is not a criticism. It is the specification, and understanding it is the difference between a deliberate defensive allocation and an accidental one. Verified August 2026.
The two Swiss indices, and which to own
| Index | Holdings | Route | TER |
|---|---|---|---|
| SMI | 20 blue chips, ~50%+ in three names | iShares SMI (CH) — CSSMI, CH0008899764, ~€2.8bn | 0.35% |
| SPI | Whole Swiss market, 200+ companies | iShares Core SPI (CH), CH0237935652 | 0.10% |
The comparison is unusually one-sided. The SPI covers the entire Swiss market including mid and small caps, contains the SMI’s giants inside it at market weight, and costs a fraction of the concentrated version. For an investor who wants Swiss exposure rather than a bet on three companies, the whole-market fund is the better instrument by a wide margin — broader, cheaper, and holding everything the narrow index holds.
This analysis sits within our side-by-side ETF comparison.
The SMI’s case is narrower: it is the headline index, the one quoted in the news and the one derivatives reference, and its concentration in defensive megacaps makes it the more defensive of the two in a downturn. Choose it deliberately if that concentration is the point. Do not choose it because it is the name you recognized.
Comparing UCITS funds? Take the decision workbook with you.
The ETF Comparison Workbook: TER, domicile, withholding and overlap checks in one printable spreadsheet.
What Swiss exposure actually does for a portfolio
Three properties make Switzerland genuinely distinctive rather than just another European market.
The sector mix is defensive by construction. Pharmaceuticals, food and staples dominate; there is essentially no technology sector and the financials are wealth managers and insurers rather than credit-cycle banks. In equity drawdowns driven by growth scares, that composition holds up better than the broad European market — and in recoveries driven by cyclicals and technology, it lags badly. Swiss equities are a defensive allocation whether or not you intended one.
The revenue is global, the listing is local. Nestlé, Roche and Novartis earn their money worldwide. Buying Swiss equities buys global consumer and healthcare franchises that happen to be listed in Zurich — the “country” exposure is much weaker than the label suggests, and much of what you actually own is already in your world core.
The franc is the position’s other half. The Swiss franc has appreciated against the euro over decades and strengthens in crises — a haven currency attached to a defensive equity market, which is why the combination has historically cushioned European portfolios. It cuts both ways: franc strength flatters the position measured in euros and pressures the earnings of the exporters inside it, which is a tension the Swiss National Bank has spent fifteen years managing.
Tax and practicalities for a euro investor
Swiss-domiciled funds sit outside the UCITS framework a European investor is used to, and the practical consequences are real. Switzerland levies 35% withholding tax on Swiss dividends — a high rate, reduced under treaty for residents of most European countries but only through a reclaim procedure that requires filing. A Swiss-domiciled fund holding Swiss equities does not solve this for a foreign investor the way an Irish fund solves US withholding.
The alternative worth checking: Irish-domiciled UCITS funds tracking Swiss indices exist and handle the treaty position differently, and for many European investors a Swiss sleeve inside a broader European fund delivers most of the exposure with none of the paperwork. Trading a Swiss-listed fund also means trading in francs, with the conversion spread charged by your broker on every purchase — a cost that can exceed the fund’s annual fee on small regular investments.
Risks
- Concentration: the SMI is three companies plus a tail; a single pharma setback moves the whole index.
- Sector gap: effectively no technology exposure — the sector that has driven global returns.
- Withholding: 35% Swiss dividend withholding with treaty relief only by reclaim.
- Currency: franc exposure that has helped historically and is not guaranteed to.
- Overlap: the giants are already in every world core at meaningful weight.
Quick-start checklist
- Check what you already own — the Swiss megacaps sit in every world fund.
- Prefer the whole-market SPI route at 0.10% unless you specifically want the three-company bet.
- Understand the 35% withholding and whether you will actually file the reclaim.
- Count the franc conversion cost on regular purchases, not just the TER.
- Size it as a defensive satellite, 3–5%, not a core.
Verdict
Swiss equities are a genuinely defensive, globally-earning, haven-currency allocation — a real diversifier for a European portfolio dominated by cyclicals and US technology. But the SMI is the wrong vehicle for most people who search for it: twenty holdings with half the weight in three companies, at three times the fee of the whole-market fund that contains them. Buy the SPI route if you want Switzerland. Buy the SMI only if you have decided, explicitly, that Nestlé, Roche and Novartis are the position.
What the Swiss market has actually returned
Switzerland’s long-run record is the reason the concentration is tolerated. Over multi-decade periods, Swiss equities have delivered returns competitive with other developed markets while doing so with notably lower volatility — the defensive sector mix producing shallower drawdowns in most equity bear markets. Add the franc’s long appreciation against the euro and the sterling, and the euro-denominated record improves further.
The pattern within that record is worth stating precisely, because it tells you when this exposure helps. Swiss equities have tended to outperform in risk-off years — the 2000–2002 technology unwind, the 2008 financial crisis, the 2022 rate shock — when pharmaceutical and staples earnings kept compounding while cyclicals collapsed. They have tended to lag badly in technology-led bull markets, which describes most of the period since 2012. An investor adding Swiss exposure is buying a lower-beta, defensively-tilted equity stream with a haven currency attached, and should expect it to look like a mistake for years at a time before it looks like foresight.
That property is the actual argument for a Swiss sleeve, and it is a portfolio-construction argument rather than a return-maximizing one. If your equity exposure is heavily US-and-technology, a Swiss allocation is one of the few developed-market additions that genuinely behaves differently rather than simply holding the same megacaps in a different wrapper.
The three companies, and the concentration risk they create
Any honest treatment of an SMI fund has to name what a fifty-percent weight in three companies means operationally.
The pharmaceutical pair carry patent-cliff risk of a kind index investors rarely think about: a single drug’s loss of exclusivity or a failed late-stage trial can remove a double-digit percentage from a company that is a fifth of your fund. That is single-stock risk arriving through an index product, and it has materialized more than once.
The food giant carries a different profile — slow, stable, globally diversified consumer earnings with pricing power, and the associated exposure to the structural questions facing packaged food: input costs, health regulation, and the ongoing debate about processed food and weight-loss drugs suppressing consumption volumes.
The rest of the index — wealth managers, insurers, luxury, industrials, precision instruments — is a genuinely high-quality tail, but it is a tail. In the SPI, the same three companies remain the largest weights, but the base beneath them is broad enough that a single patent setback is a bad day rather than a structural event. That is the case for the whole-market fund restated as risk rather than as fees.
How to build the Swiss position in practice
Three routes exist and they differ more in friction than in exposure.
The Swiss-domiciled funds — the SMI and SPI products listed in Zurich — give the cleanest tracking of the domestic indices and the most direct exposure. They also mean trading in francs, paying your broker’s currency conversion on every purchase, and dealing with the Swiss withholding position yourself.
An Irish-domiciled UCITS fund tracking a Swiss index, where available, removes the conversion friction if a euro line exists and handles treaty matters at fund level. For regular savers this is usually the lower-total-cost route even at a slightly higher headline fee, because conversion charges on monthly purchases compound faster than a few basis points of TER.
A broad European fund, which holds Switzerland at roughly its market weight alongside the rest of the continent. For most portfolios this is enough, and the dedicated sleeve is only worth the effort if the defensive tilt is specifically what you want.
Whichever route, the sizing discipline is the same as any single-country satellite: 3–5%, decided in advance, summed with every other country position, and reviewed against the reason you bought it rather than against last year’s return.
Frequently asked questions
What is the SMI?
Switzerland’s blue-chip index — twenty of the largest and most liquid Swiss companies, historically with Nestlé, Roche and Novartis around half the total weight.
SMI or SPI?
SPI for Swiss exposure: the whole market, 200+ companies, at 0.10%. SMI only if the concentration in three defensive megacaps is deliberately what you want.
Why does Switzerland have no tech sector?
Its listed market grew around pharmaceuticals, food, precision manufacturing and wealth management. The absence is structural and explains both the defensiveness and the lag in technology-led rallies.
How is Swiss dividend withholding handled?
Switzerland withholds 35%, with treaty relief available to most European residents only through a reclaim procedure. Budget for the friction, or hold the exposure inside a broader fund.
Do I already own Swiss equities?
Yes — the Swiss megacaps are constituents of every MSCI World and All-World fund. A Swiss sleeve adds weight rather than new exposure.
Is the franc part of the return?
A large part of it for a euro investor. The franc’s long appreciation has added materially to Swiss equity returns measured in euros, and it strengthens in crises — which is much of the diversification value.
Why are Swiss equities less volatile?
The sector mix — pharmaceuticals, food and staples dominate, with no technology sector and insurers rather than credit-cycle banks. Defensive earnings produce shallower drawdowns.
When does Swiss exposure help?
In risk-off years — 2000–2002, 2008, 2022. It lags badly in technology-led bull markets, which describes most of the last decade.
What is patent-cliff risk?
A drug losing exclusivity or failing a late-stage trial can remove a double-digit percentage from a company that is a fifth of an SMI fund — single-stock risk arriving through an index product.
Does the SPI include the SMI companies?
Yes, at market weight, inside a base of 200+ companies — which is why it delivers the same exposure with materially less concentration risk at a lower fee.
Is the franc’s appreciation likely to continue?
It has been a long-running feature driven by haven demand and low inflation, and the Swiss National Bank has spent years resisting it. Past appreciation is not a forecast.
Should I buy Swiss or broad European exposure?
A broad European fund holds the Swiss giants already. A dedicated sleeve is a deliberate defensive tilt, appropriate mainly for portfolios heavy in US technology.
Swiss-listed or Irish-domiciled fund?
Irish-domiciled with a euro line is usually the lower total cost for regular savers, because conversion charges on monthly purchases compound faster than a few basis points of fee.
How much Switzerland should I hold?
3–5% as a deliberate defensive satellite, summed with every other country position, or nothing beyond what a broad European or world fund already provides.
Cited sources: iShares fund data, justETF data, and SIX index data. Verify current fund figures before investing. Educational content, not financial advice.
European UCITS/ETF investor with 11+ years building a global dividend and index portfolio, and founder of Financial Expert Class. I write every guide here from first-hand experience investing across EU brokers and tax regimes — not theory. More about me →